anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Application of pulp regenerative cell therapy for mature teeth with periapical lesions is a critical clinical challenge. The bacterial infection in inaccessible location within the root canal system and in the periapical lesions could cause resistance and impediment, leading to limitations in successful therapy. Thus, the aim of this study was to examine the effect of residual bacteria on the outcome of pulp regeneration in mature teeth with apical periodontitis in dogs.
METHODS: Periapical lesions were induced in 32 root canals of 4 dogs in two different models in severities, model A and model B. Model A (moderate infection): the canal exposed to the oral cavity for 2 weeks and then closed for 2 weeks. Model B (severe infection): the canal exposed to the oral cavity for 2 months and then closed for 5 months. All root canals were irrigated with 6% sodium hypochlorite, and 3% EDTA and further with 0.015% levofloxacin-containing nanobubbles, which was also used as an intracanal medicament. The aseptic conditions were examined by bacterial anaerobic culture and/or PCR analyses. The root canal treatment was repeated several times, and allogeneic dental pulp stem cells were transplanted into the root canals. The radiographic evaluation of periapical lesions was performed by cone-beam computed tomography before the first treatment, just after cell transplantation, and after 2 months and 6 months in both model A, model B, respectively. The animals were then sacrificed and the jaw blocks were harvested for histological and histobacteriological evaluations of pulp regeneration and periapical tissue healing. Furthermore, the DiI-labelled DPSCs were transplanted into the root canals after complete disinfection (n = 4) or without root canal treatment (n = 4) in the apical periodontitis model (model A) in one dog, and cell localization was compared 72 h after transplantation.
RESULTS: In 8 out of 12 canals from model A, and 10 out of 15 canals from model B, pulp regeneration with good vascularization, innervation, and a significant reduction in the radiolucent area of the periapical lesions were observed. However, in the other 4 canals and 5 canals from model A and model B, respectively, no pulp tissue was regenerated, and inflammation in the periapical tissue, and external resorption or healed external resorption were detected. The presence of residual bacteria in the periapical tissues and severe inflammation were significantly associated with inhibition of regenerated pulp tissue in these 9 unsuccessful canals (P < 0.05, each) (OR = 0.075, each) analyzed by multiple logistic regression analysis. For cellular kinetics, transplanted cells remained in the disinfected root canals, while they were not detected in the infected root canals, suggesting their migration through the apical foramen under the influence of inflammation.
CONCLUSIONS: A true pulp-dentin complex was regenerated in the root canal by the pulp regenerative therapy in mature teeth with apical lesions. The successful pulp regeneration was negatively associated both with residual bacteria and inflammation in the periapical tissue.
A large proportion of extremely preterm infants are mechanically ventilated through the use of endotracheal intubation. However, clinicians try to avoid intubation due to the complications that may arise from being mechanically ventilated such as ventilator associated pneumonia (VAP), pulmonary hemorrhage, air leak etc. In order to the prevent these complications, clinicians accelerate weaning and provide non-invasive respiratory support. The most commonly used type of non-invasive respiratory support following extubation is nasal continuous positive airway pressure (NCPAP). NCPAP has been shown to improve oxygenation, reduce airway resistance, increase tidal volume, stabilize chest wall and maintain functional residual capacity. In addition to NCPAP, nasal intermittent positive pressure ventilation (NIPPV) has become a popular choice as a post-extubation respiratory support mode. However, there is a lack of knowledge regarding the effects of synchronization between the infant's own spontaneous respiratory efforts and ventilator inflations.

Synchronization, especially during non-invasive ventilation, is difficult to achieve in preterm infants due to their rapid respiratory rates, short inspiratory times, periodic breathing, leaks and small tidal volumes. Previous studies have used devices such as an abdominal capsule to allow for synchronization while the infant is receiving NIPPV. The abdominal capsule itself is prone to incorrect placement, time delays and ineffective synchronization. Neurally Activated Ventilatory Assistance (NAVA) is a new technology that can be used during invasive and non-invasive ventilation. In this novel mode, the electrical activity of the diaphragm, called EAdi, is detected be electrodes inserted at the tip of a specialized nasogastric tube. The EAdi represents the patient's inherent neural respiratory drive. The ventilator assists each spontaneous breath by delivering pressure that is linearly proportional to the EAdi. The mechanical breath is initiated at the start of diaphragmatic contraction and maintained until the EAdi is at 60 to 70% of the peak pressure generated. Therefore, the inspiratory time, expiratory time and peak inflation pressure are all controlled and determined by the patient, providing patient-ventilator synchrony.
Use of a glycolysis-inhibiting compound, for the preparation of a composition for reducing and/or delaying the hyperproliferation disorder of epidermic cells. An independent claim is included for a method of identifying the glycolysis inhibiting compound comprising preparing a keratinocyte culture, adding the compound to be tested in the cell culture medium, comparing the glycolysis levels or the GLUT-1 expression level in the keratinocytes in the presence of the compound to be tested with the glycolysis rate or the expression level in a sample without cultivated compound to be tested and selecting the compound that decreases the glycolysis rate of at least 25% or decreases the GLUT-1 expression of at least 25%. ACTIVITY : Cytostatic; Antipsoriatic; Depilatory. MECHANISM OF ACTION : Glucose transporter (GLUT) inhibitor. The ability of the glycolysis-inhibiting compound to inhibit the glucose transporter was tested. The result showed that the glycolysis-inhibiting compound decreased the proliferation after 74 hours treatment of the keratinocytes at a concentration of 1mM.
A compound of formula (I) given in the description, wherein Ring A is imidazol[1,2-a]pyrid-3-yl or pyrazolo[2,3-a]pyrid-3-yl; R2 is as defined within; m is 0-5; wherein the values of R2 may be the same or different; R1 is as defined within; n is 0 to 2, wherein the values of R1 may be the same or different; Ring B is phenyl or phenyl fused to a C5-7 cycloalkyl ring; R3 is as defined within; p is 0-4; wherein the values of R3 may be the same or different; R4 is as defined within; q is 0-2; wherein the values of R4 may be the same or different, and wherein p+q .? 5; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. The use of compounds of formula (I) in the inhibition of cell cycle kinases CDK2 and CDK6 are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed. 12 claims
Secondary malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have been reported in studies of pediatric patients who have received Dexrazoxane for Injection in combination with chemotherapy. Dexrazoxane for Injection is not indicated for use in pediatric patients. Some adult patients who received Dexrazoxane for Injection in combination with anti-cancer agents known to be carcinogenic have also developed secondary malignancies, including AML and MDS.   
  
  
  
Razoxane is the racemic mixture, of which dexrazoxane is the S(+)-enantiomer. Secondary malignancies (primarily acute myeloid leukemia) have been reported in patients treated chronically with oral razoxane. In these patients, the total cumulative dose of razoxane ranged from 26 to 480 grams and the duration of treatment was from 42 to 319 weeks. One case of T-cell lymphoma, one case of B-cell lymphoma, and six to eight cases of cutaneous basal cell or squamous cell carcinoma have also been reported in patients treated with razoxane. Long-term administration of razoxane to rodents was associated with the development of malignancies  [see Nonclinical Toxicology (13.1)].
A single dose of Reclast should not exceed 5 mg and the duration of infusion should be no less than 15 minutes [see Dosage and Administration (2)].

Reclast is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment [see Contraindications (4)]. If history or physical signs suggest dehydration, Reclast therapy should be withheld until normovolemic status has been achieved [see Adverse Reactions (6.2)].

Reclast should be used with caution in patients with chronic renal impairment. Acute renal impairment, including renal failure, has been observed following the administration of zoledronic acid, especially in patients with preexisting renal compromise, advanced age, concomitant nephrotoxic medications, concomitant diuretic therapy, or severe dehydration occurring before or after Reclast administration. Acute renal failure (ARF) has been observed in patients after a single administration. Rare reports of hospitalization and/or dialysis or fatal outcome occurred in patients with underlying moderate to severe renal impairment or with any of the risk factors described in this section [see Adverse Reactions (6.2)]. Renal impairment may lead to increased exposure of concomitant medications and/or their metabolites that are primarily renally excreted [see Drug Interactions (7.4)].

Creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each Reclast dose. Transient increase in serum creatinine may be greater in patients with impaired renal function; interim monitoring of creatinine clearance should be performed in at-risk patients. Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. These patients should have their fluid status assessed and be appropriately hydrated prior to administration of Reclast. Reclast should be used with caution with other nephrotoxic drugs [see Drug Interactions (7.3)]. Consider monitoring creatinine clearance in patients at-risk for ARF who are taking concomitant medications that are primarily excreted by the kidney [see Drug Interactions (7.4)].
Subjects will be given up to 0.5 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
The present invention relates to a Chinese wolfberry cake and a preparation process thereof, which belongs to health food. The Chinese wolfberry cake comprises the ingredients of 85 to 95% of Chinese wolfberry, 2 to 6% of water, 2 to 6% of white sugar and 0.5 to 4% of edible oil. The present invention has the advantages of keeping of the specific red of the Chinese wolfberry, proper hardness, good mouth feelings, portability, sanitation, etc. The Chinese wolfberry cake of the present invention can be eaten as a dessert a health product and tonic food. The present invention does not have any side effect and is suitable for the elderly and the young, and the Chinese wolfberry cake of the present invention, which is eaten by patients with diabetes, diseases of the liver and kidney, eye diseases, etc. for a long time, has obvious effect.
Combined vaccine against the causative agents of AIDS, bilharziosis and tuberculosis contain as active ingredient 'masked' bacteria. Also new are 'masked' BCG cells. Bacteria are masked by binding to their surface partially oxidised polysaccharide (I) which in turn is covered with viral or parasitic proteins, peptides or synthetic epitopes. (I) is esp. dextran (but can also be starch, cellulose, pectin, lipopolysaccharide etc.) and bacteria are esp. BCG (but other attenuated mycobacteria can be used. USE/ADVANTAGE - This vaccine provides greater non-specific and specific humoral or cellular immune response to the specified organisms. It can be used for prevention or (after infection) for protection, and does not require an adjuvant
FIELD: veterinary science. ^ SUBSTANCE: method includes introduction of probiotic containing cultures of bifidus bacteria, streptococci and bacteria Bacillus subtilis into digestive tract of suckling piglets. Daily dose of probiotic prior to feeding is introduced into 5-10 ml of solution, including 84.3-89.5% decoction of witloof chicory, 10-15% of glucose and 0.5-0.7% of ascorbic acid and having temperature of 15-20C. Solution is bottle-fed to piglets individually in amount of 5-10 ml per head per day in 1-2 stages daily for 10-15 days. ^ EFFECT: method makes it possible to stimulate healthy microflora of intestine and to increase average daily growth of live mass of piglets. ^ 1 tbl, 4 ex
Numerous studies use numerical variables of neck movement to predict the level of severity of a pathology. However, the correlation between these numerical variables and disability levels is low, less than 0.4 in the best cases, even less in subjects with nonspecific neck pain. This work aims to use Functional Data Analysis (FDA), in particular scalar-on-function regression, to predict the Neck Disability Index (NDI) of subjects with nonspecific neck pain using the complete movement as predictors. Several functional regression models have been implemented, doubling the multiple correlation coefficient obtained when only scalar predictors are used. The best predictive model considers the angular velocity curves as a predictor, obtaining a multiple correlation coefficient of 0.64. In addition, functional models facilitate the interpretation of the relationship between the kinematic curves and the NDI since they allow identifying which parts of the curves most influence the differences in the predicted variable. In this case, the movement's braking phases contribute to a greater or lesser NDI. So, it is concluded that functional regression models have greater predictive capacity than usual ones by considering practically all the information in the curve while allowing a physical interpretation of the results.
The invention discloses a polypeptide analog for resisting heart implant vasculopathy, and a corresponding cDNA (complementary deoxyribonucleic acid) and application thereof. On the basis of the establishment of the TIMP-1 and MMP-14 interaction structure field in CAV, the invention provides a method for producing a recombinant polypeptide analog myc HisA-TIMP-1[triangle102-217aa] by a gene engineering process. The polypeptide analog has the advantages of high expression efficiency and simple purification technique, and is beneficial to further large-scale preparation. The polypeptide analog can promote the interaction between TIMP-1 and MMP-14, inhibit the VSMC transfer after heart transplantation and inhibit the CAV from generation and development. The polypeptide analog can provide theoretical references for searching for effective intervention target spots for CAV and developing new therapeutic drugs. The polypeptide analog has very important development prospects for implementing long-term survival of heartmen after CAV clinical therapy.
A scrubber mitt comprising a backing, a plurality of loops and a cavity. The backing may have an inner side and an outer side. The plurality of loops may be attached to the outer side. The cavity may be defined by the inner side. The cavity is adapted to fit around the hand of a person. There is also disclosed a process comprising disposing the scrubber mitt around a hand of a person and introducing a liquid cleanser into a reservoir defined by the backing.
This study investigated the role of mitochondrial dynamics in postoperative cognitive dysfunction (POCD) and assessed the therapeutic potential of mitochondrial modulation, particularly through the inhibition of dynamin-related protein 1 (DRP1) with Mdivi-1. Our findings indicated that DRP1 inhibition substantially mitigated neuroinflammation mediated by microglial cells, contributing to improved cognitive function in POCD models. The administration of Mdivi-1 led to a notable decrease in mitochondrial fission, reduced reactive oxygen species (ROS) production, and stabilization of mitochondrial membrane potential, all of which correlate with diminished neuroinflammation, as evidenced by lower NOD-like receptor family pyrin domain containing 3 (NLRP3)/ interleukin-1β (IL-1β) expression in microglial cells. Importantly, Mdivi-1 treatment was also found to enhance synaptic plasticity, increasing synaptic spine density in the hippocampal region of POCD mice. This improvement in mitochondrial health and synaptic integrity was paralleled by enhanced cognitive performance, as demonstrated in Y-maze tests. These results underscored the critical role of mitochondrial dynamics in the pathophysiology of POCD and suggested that targeting mitochondrial dysfunction, specifically through DRP1 inhibition, could be an effective approach for POCD treatment.
The music-with-movement exercise program (MMEP) is an 8-week program. In the first 4 weeks a center-based program will be offered in the District Elderly Centers, and from week 1 to week 8 home-based and digital-based activities will be delivered via a WhatsApp group.
The present invention addresses the problem of providing a conjugate which is useful in a pretargeting method and composed of a biotin-modified dimer and a duocarmycin derivative. According to the present invention, provided is a compound represented by formula (1) or (2). (In the formula, R 1  and R 2  each independently represent a hydrogen atom, a lower alkyl group, or a lower alkoxycarbonyl group. One among R 3 , R 4 , and R 5  represents -O-L 7 -(Xaa) m -L 6 -N 3 , and the other two each independently represent a hydrogen atom, a lower alkyl group, or a lower alkoxyl group. X represents a reactive group. L 6  and L 7  each independently represent a divalent linking group. Xaa represents an amino acid residue. m represents an integer of 2-10. Me represents a methyl group.)
An antibacterial composition containing the extracts of Schizandra sp. and Rubus coreanus is provided to have excellent antibacterial activity and improve safety without side effect. An antibacterial composition to helicobacter pylori comprises the extracts of Schizandra sp. and Rubus coreanus as active ingredients. The extracts are isolated using water and alcohol of 1-4 carbon atoms. The composition further comprises carbohydrate, lipid, vitamin, and mineral. The composition prevents and treats gastroduodenal disorder. The gastroduodenal disorder comprises gastric ulcer, duodenal ulceration and gastric cancer.
TAK-228, milled capsule, orally, once daily, on an empty stomach in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 2 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 2 mg, once daily, is safe and tolerable, then the dose will be escalated to 4 mg, once daily, until RP2D is determined.
PROBLEM TO BE SOLVED: To obtain a new quinoline compound having excellent selectivity to muscarine M3 receptor, especially selectivity to muscarine M3 receptor of ileum, further having excellent selectivity to muscarine M3 receptor compared with muscarine M2 receptor and useful as a muscarine M3 receptor antagonistic agent. SOLUTION: The objective compound is expressed by formula I (R is A-W-B or a 5-10C alkenyl; A is a lower alkylene; W is none or O; B is a lower cycloalkyl, phenyl which may contain one or more substituents on the ring or the like), e.g. (+)-3-[(S)-1-phenethylpyrrolidin-3-yl]-3-phenyl-3,4-dihydro-1H- quinolin-2-one. The compound of formula I can be produced e.g. by reacting a compound of formula III synthesizable from a compound of formula II with a compound of the formula R-Y (Y is an eliminable group) (e.g. phenethyl tosylate) in an organic solvent such as acetonitrile in the presence of a base such as potassium carbonate.
BACKGROUND AND AIMS: Obesity and insulin resistance are associated with left ventricular diastolic dysfunction (LVDD) and increased risk of heart failure. Cardiometabolic index (CMI) and triglyceride glucose (TyG) are new indexes to assess visceral obesity and insulin resistance, respectively. The study aimed to investigate the clinical usefulness of these indexes for identifying LVDD individuals.
METHODS AND RESULTS: Overall, 1898 asymptomatic individuals were included in this cross-sectional study. Participants underwent anthropometrics, serum biochemical evaluation, and echocardiography. Multiple linear regression analysis revealed that both indexes were independent determinants of diastolic parameters among females; while for males, CMI and TyG were not associated with A velocity. In the multivariate logistic analysis, the proportion of LVDD in the third and fourth quartiles of CMI remained significantly greater than that in the lowest quartile in females (Q3 vs. Q1: odds ratio (OR) = 2.032, 95% confidence interval (CI): 1.181-3.496; Q4 vs. Q1: OR = 2.393, 95% CI: 1.347-4.249); while in males, the incidence of LVDD was significantly greater only in the fourth quartile. For TyG, the presence of LVDD in the fourth quartile was significantly greater in both genders. The discriminant values between the CMI (AUC: 0.704, 95% CI: 0.668-0.739) and TyG (AUC: 0.717, 95% CI: 0.682-0.752) were similar in females. Both indexes performed better in females than in males to identify LVDD.
CONCLUSION: The CMI and TyG might both serve as effective tools to identify LVDD in routine health check-ups in primary care, mainly in females. With simpler parameters, the CMI could be utilized in medically resource-limited areas.
Participants will be required to fast each day for 12 weeks and will be given lifestyle recommendations with respect to diet and exercise. The registered dietitian (RD) will obtain a baseline dietary record and provide counseling on the time-restricted eating regimen. The RD will collect the participant's normal diet and exercise routine. Counseling will involve instructing the participant to choose an eight-hour eating window (e.g., 10:00am - 6:00pm) during which the participant will be able to eat. During the 16-house fasting window (e.g., 6:00pm - 10:00 am), the participant is able to drink regular water and black coffee or tea. The RD will be available to answer any questions the participants may have pertaining to the regimen and will instruct the participants regarding standard of care lifestyle recommendations. This includes education of a low-calorie diet (500-1000 kcal) and moderate-intensity exercise.